Amoscanate
Amoscanate Basic information
- Product Name:
- Amoscanate
- Synonyms:
-
- 4-Isothiocyanato-N-(4-nitrophenyl)benzenamine
- C-9333 GO
- CGP-4540
- CIBA-9333 GO
- Nithiocyamine
- 4-Nitro-4'-iso-thiocyanate diphenyl amine
- Benzenamine, 4-isothiocyanato-N-(4-nitrophenyl)-
- amoscanate USP/EP/BP
- CAS:
- 26328-53-0
- MF:
- C13H9N3O2S
- MW:
- 271.29
- Mol File:
- 26328-53-0.mol
Amoscanate Chemical Properties
- Melting point:
- 196-198°
- Boiling point:
- 469.7±30.0 °C(Predicted)
- Density
- 1.3474 (rough estimate)
- refractive index
- 1.6740 (estimate)
- pka
- -3.50±0.40(Predicted)
- form
- Solid
- color
- Crystals from acetone
Amoscanate Usage And Synthesis
Chemical Properties
Orange-yellow crystalline powder, odorless and tasteless. Melting point 196-198°C. Insoluble in water, slightly soluble in acetone, chloroform, benzene and ethanol.
Uses
Amoscanate (cgp4540) is phenyl isothiocyanate in which the hydrogen at the para-position has been replaced by a 4-nitroanilinyl group. Amoscanate is an anti-schistosomal agent. Amoscanate, as an isothiocyanate compound and uncoupler of oxidative phosphorylation, potently injures rodent ependyma[1].
Definition
ChEBI: Amoscanate is an isothiocyanate that is phenyl isothiocyanate in which the hydrogen at the para- position has been replaced by a 4-nitroanilinyl group. It has a role as a schistosomicide drug. It is a C-nitro compound, an isothiocyanate and a secondary amino compound. It is functionally related to a diphenylamine.
Safety Profile
Mutation data reported. Ananthelmintic agent.
in vivo
Amoscanate (500 mg/kg; p.o.; 10 days) destructs ependyma and periventricular brain[1].
Amoscanate (250 and 500 mg/kg; p.o.; 28 days) elicits necrosis, Ca++-positive microgranules, pyknosis and edema localized in ependyma/subependyma in the medial striatum[1].
Amoscanate (25~500 mg/kg; p.o.; 20 days) elicits progressive necrosis of ependyma[1].
Amoscanate elicits massive ultrastructural damage in ependymal cells[1].
| Animal Model: | Sprague-Dawley rats[1] |
| Dosage: | 500 mg/kg |
| Administration: | P.o.; 10 days |
| Result: | Destructed ependyma and periventricular brain. |
| Animal Model: | Sprague-Dawley rats[1] |
| Dosage: | 250 and 500 mg/kg |
| Administration: | P.o.; 28 days |
| Result: | Elicited necrosis, Ca++-positive microgranules, pyknosis and edema localized in ependyma/subependyma in the medial striatum. |
| Animal Model: | Sprague-Dawley rats[1] |
| Dosage: | 25~500 mg/kg |
| Administration: | P.o.; 20 days |
| Result: | Elicited progressive necrosis of ependymal. |
IC 50
Schistosome
References
[1] Johanson C, et al. The distributional nexus of choroid plexus to cerebrospinal fluid, ependyma and brain: toxicologic/pathologic phenomena, periventricular destabilization, and lesion spread. Toxicol Pathol. 2011;39(1):186-212. DOI:10.1177/0192623310394214
Amoscanate Preparation Products And Raw materials
Raw materials
AmoscanateSupplier
- Tel
- 0571-82693216
- info@yuhaochemical.com
- Tel
- 020-39119399 18927568969
- isunpharm@qq.com
- Tel
- 021-61312847; 18021002903
- 3008007409@qq.com
- Tel
- +1-781-999-5354; +17819995354
- marketing@targetmol.com
- Tel
- +86-29-89586680 +86-15129568250
- 1026@dideu.com